<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Silo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property Portfolio</title>
<style>
body { font-family: Arial, Helvetica, sans-serif; background:#0f1115; color:#e6e6e6; margin:0; padding:40px; }
.container { max-width:700px; margin:auto; background:#161a21; border-radius:10px; padding:32px; box-shadow:0 0 30px rgba(0,0,0,0.4); }
h1 { margin-top:0; color:#4da3ff; }
table { width:100%; margin-top:12px; border-collapse:collapse; }
th, td { text-align:left; padding:6px 8px; border-bottom:1px solid #2a2f3a; }
ul { margin-top:12px; padding-left:20px; }
.section { margin-top:24px; }
.small { margin-top:12px; font-size:13px; color:#999; }
a { color:#4da3ff; }
</style>
</head>
<body>
  <div class="container">
    <h1>Silo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property Portfolio</h1>

    <table>
      <tr><th>Ticker</th><td>SILO</td></tr>
      <tr><th>Float</th><td>12.2 M</td></tr>
      <tr><th>IO</th><td>16.41%</td></tr>
      <tr><th>MC</th><td>4.0 M</td></tr>
      <tr><th>Extra Info</th><td>None</td></tr>
    </table>

    <div class="section">
      <strong>Summary</strong>
      <p>Silo Pharma announced the Japan Patent Office issued a Notice of Allowance for a patent application covering its lead asset SPC-15, an intranasal therapeutic targeting PTSD. The allowed application, titled "Compositions and Methods for the Prevention of Stress-Induced Fear, Depression-Like Behavior, and Anxiety-Like Behavior," covers composition and method claims and is expected to be granted shortly. Company states the allowance strengthens its intellectual property estate in a key pharmaceutical jurisdiction and supports protection of its core scientific innovations. Silo is a developmental-stage biopharmaceutical and cryptocurrency treasury company with other programs including SP-26 and preclinical CNS assets.</p>
    </div>

    <div class="section">
      <strong>Positives</strong>
      <ul><li>Japan Patent Office issued a Notice of Allowance for SPC-15 patent application, indicating examiner found it patentable</li><li>Allowed claims cover both compositions and methods related to preventing stress-induced behavioral responses</li><li>Expands Silo's international intellectual property portfolio in a significant pharmaceutical market</li></ul>
    </div>

    <div class="section">
      <strong>Negatives</strong>
      <ul><li>Notice of Allowance indicates impending grant but is not the final issued patent</li><li>Silo is a developmental-stage company; lead asset commercialization and clinical success are not guaranteed</li><li>Article contains forward-looking statements and provides no timeline or specifics on claim scope, enforcement, or commercial plans</li></ul>
    </div>

    <div class="section">
      <a href="https://news.nuntiobot.com/article/089063c9-2019-4425-b12e-60c6aad30b91" target="_blank">Original Article</a>
    </div>

    <div class="small">SILO â€¢ TradersLink AI News</div>
  </div>
</body>
</html>